{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:32:04Z","timestamp":1793442724909,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["15486"],"award-info":[{"award-number":["15486"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115451","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:58:09Z","timestamp":1791561489000},"page":"115451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Combining imaging strategies with physiologically-based pharmacokinetic modeling to improve precision dosing & drug delivery in brain tumors"],"prefix":"10.1016","volume":"399","author":[{"given":"Tamara","family":"Jordens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Ja\u00ebl","family":"Elskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jconrel.2026.115451_bb0005","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115451_bb0010","article-title":"Relationship between biodistribution and tracer kinetics of (11)C-erlotinib, (18)F-afatinib and (11)C-osimertinib and image quality evaluation using pharmacokinetic\/pharmacodynamic analysis in advanced stage non-small cell lung cancer patients","volume":"12","author":"van de Stadt","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115451_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091446","article-title":"Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier","volume":"13","author":"Angeli","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115451_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104297","article-title":"Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)","volume":"146","author":"van Hoppe","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115451_bb0030","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s11095-014-1389-0","article-title":"ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors","volume":"31","author":"Deng","year":"2014","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0035","first-page":"105","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115451_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae241","article-title":"The STELLAR trial: a phase II\/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma","volume":"6","author":"Janssen","year":"2024","journal-title":"Brain Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115451_bb0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-021-03834-3","article-title":"Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation","volume":"154","author":"Cardona","year":"2021","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-022-04145-x","article-title":"Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer","volume":"160","author":"Hui","year":"2022","journal-title":"J. Neuro-Oncol."},{"issue":"14","key":"10.1016\/j.jconrel.2026.115451_bb0055","doi-asserted-by":"crossref","first-page":"15090","DOI":"10.1002\/cam4.6180","article-title":"Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115451_bb0060","article-title":"Osimertinib plasma trough concentration in relation to brain metastases development in patients with advanced EGFR-mutated NSCLC","volume":"5","author":"Gulikers","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115451_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091844","article-title":"Exposure-response analysis of osimertinib in patients with advanced non-small-cell lung cancer","volume":"14","author":"Rodier","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115451_bb0070","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115451_bb0075","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/mp400533q","article-title":"A physiologically based modeling strategy during preclinical CNS drug development","volume":"11","author":"Ball","year":"2014","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115451_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091402","article-title":"Physiologically based pharmacokinetic (PBPK) modeling for predicting brain levels of drug in rat","volume":"13","author":"S\u00e1nchez-Dengra","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115451_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020226","article-title":"Interspecies brain PBPK modeling platform to predict passive transport through the blood-brain barrier and assess target site disposition","volume":"16","author":"Mehta","year":"2024","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115451_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1208\/s12248-021-00675-w","article-title":"In vitro to in vivo extrapolation linked to physiologically based pharmacokinetic models for assessing the brain drug disposition","volume":"24","author":"Murata","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.115451_bb0100","series-title":"PET-Guided Physiologically-Based Pharmacokinetic Modeling of Tyrosine Kinase Inhibitors in NSCLC Patients With Brain Metastases","author":"Jordens","year":"2025"},{"issue":"15","key":"10.1016\/j.jconrel.2026.115451_bb0105","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-22-0405","article-title":"Mechanistic modeling of central nervous system pharmacokinetics and target engagement of HER2 tyrosine kinase inhibitors to inform treatment of breast cancer brain metastases","volume":"28","author":"Li","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115451_bb0110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cpt.3505","article-title":"Mechanistic modeling of spatial heterogeneity of drug penetration and exposure in the human central nervous system and brain tumors","volume":"117","author":"Li","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115451_bb0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s11095-021-03154-1","article-title":"The extension of the LeiCNS-PK3.0 model in combination with the \"handshake\" approach to understand brain tumor pathophysiology","volume":"39","author":"Hirasawa","year":"2022","journal-title":"Pharm. Res."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2026.115451_bb0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-409X(00)00107-1","article-title":"Methodological issues in microdialysis sampling for pharmacokinetic studies","volume":"45","author":"de Lange","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115451_bb0125","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/psp4.70006","article-title":"Physiologically based pharmacokinetic model of tyrosine kinase inhibitors to predict target site penetration, with PET-guided verification","volume":"14","author":"van der Gaag","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115451_bb0130","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cts.13500","article-title":"Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: a positron emission tomography and magnetic resonance imaging study","volume":"16","author":"Ekman","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115451_bb0135","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2967\/jnumed.117.195800","article-title":"Molecular imaging of ABCB1 and ABCG2 inhibition at the human blood-brain barrier using elacridar and (11)C-erlotinib PET","volume":"59","author":"Verheijen","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115451_bb0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00234-010-0740-3","volume":"53","author":"Server","year":"2011","journal-title":"Neuroradiology"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115451_bb0145","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/cts.12978","article-title":"Quantitative protein expression of blood-brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer","volume":"14","author":"Bao","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.1211","article-title":"Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle","volume":"106","author":"Bartelink","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115451_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clbc.2019.07.011","article-title":"Pre- and postoperative neratinib for HER2-positive breast cancer brain metastases: translational breast cancer research consortium 022","volume":"20","author":"Freedman","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jconrel.2026.115451_bb0160","article-title":"Comparing DESI-MSI and MALDI-MSI mediated spatial metabolomics and their applications in cancer studies","volume":"12","author":"He","year":"2022","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115451_bb0165","doi-asserted-by":"crossref","first-page":"10146","DOI":"10.1021\/acs.analchem.5b02998","article-title":"Mapping drug distribution in brain tissue using liquid extraction surface analysis mass spectrometry imaging","volume":"87","author":"Swales","year":"2015","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/neuonc\/noab197","article-title":"Multimodal platform for assessing drug distribution and response in clinical trials","volume":"24","author":"Lopez","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"786","key":"10.1016\/j.jconrel.2026.115451_bb0175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn6274","article-title":"A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma","volume":"17","author":"Rendo","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115451_bb0180","article-title":"Towards novel biomimetic in vitro models of the blood-brain barrier for drug permeability evaluation","volume":"10","author":"M\u00e1rmol","year":"2023","journal-title":"Bioengineering (Basel)"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115451_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050574","article-title":"Evaluation of drug blood-brain-barrier permeability using a microfluidic chip","volume":"16","author":"Yang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115451_bb0190","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115451_bb0195","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fcell.2020.00220","article-title":"Organoid models of glioblastoma to study brain tumor stem cells","volume":"8","author":"Azzarelli","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"16","key":"10.1016\/j.jconrel.2026.115451_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18162601","article-title":"Construction strategies, microenvironmental modelling and precision-therapy applications of glioma organoid models","volume":"18","author":"Chen","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115451_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.900450","article-title":"Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview","volume":"12","author":"Van De Stadt","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:51:35Z","timestamp":1793440295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S0168365926008552"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115451","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining imaging strategies with physiologically-based pharmacokinetic modeling to improve precision dosing & drug delivery in brain tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115451"}}